\contentsline {section}{\numberline {1}Introduction}{5}{section.1}%
\contentsline {subsection}{\numberline {1.1}The Imperative for AI in Clinical Trials}{5}{subsection.1.1}%
\contentsline {subsection}{\numberline {1.2}Scope and Structure of the Review}{7}{subsection.1.2}%
\contentsline {section}{\numberline {2}Foundational Landscape: Early Explorations and Challenges}{8}{section.2}%
\contentsline {subsection}{\numberline {2.1}Initial Vision and Broad Applications}{8}{subsection.2.1}%
\contentsline {subsection}{\numberline {2.2}Identified Bottlenecks and Early Hurdles}{11}{subsection.2.2}%
\contentsline {section}{\numberline {3}Core AI Methodologies for Trial Optimization}{13}{section.3}%
\contentsline {subsection}{\numberline {3.1}AI-Driven Patient Recruitment and Matching}{13}{subsection.3.1}%
\contentsline {subsection}{\numberline {3.2}Optimizing Clinical Trial Design and Protocol Generation}{16}{subsection.3.2}%
\contentsline {subsection}{\numberline {3.3}Enhancing Operational Efficiency and Monitoring}{18}{subsection.3.3}%
\contentsline {section}{\numberline {4}Advanced AI for Data Integration and Strategic Insights}{21}{section.4}%
\contentsline {subsection}{\numberline {4.1}Leveraging Real-World Evidence (RWE) with AI}{21}{subsection.4.1}%
\contentsline {subsection}{\numberline {4.2}Privacy-Preserving Data Analysis: Federated Learning}{23}{subsection.4.2}%
\contentsline {subsection}{\numberline {4.3}Synthetic Data Generation for Data Scarcity and Privacy}{25}{subsection.4.3}%
\contentsline {subsection}{\numberline {4.4}Knowledge Graphs for Predictive Modeling}{27}{subsection.4.4}%
\contentsline {section}{\numberline {5}Advanced AI Paradigms for Dynamic Trial Management and Upstream Impact}{30}{section.5}%
\contentsline {subsection}{\numberline {5.1}Large Language Models (LLMs) for Documentation and Synthesis}{30}{subsection.5.1}%
\contentsline {subsection}{\numberline {5.2}Reinforcement Learning for Adaptive Trial Designs}{33}{subsection.5.2}%
\contentsline {subsection}{\numberline {5.3}AI in Early Drug Discovery and Pre-clinical Development}{35}{subsection.5.3}%
\contentsline {section}{\numberline {6}Ensuring Trustworthy AI: Fairness, Explainability, and Human Factors}{37}{section.6}%
\contentsline {subsection}{\numberline {6.1}Addressing AI Fairness and Bias in Clinical Predictions}{37}{subsection.6.1}%
\contentsline {subsection}{\numberline {6.2}Explainable AI (XAI) for Interpretability and Trust}{39}{subsection.6.2}%
\contentsline {subsection}{\numberline {6.3}Human Factors and Usability in AI-Driven Systems}{42}{subsection.6.3}%
\contentsline {section}{\numberline {7}Evaluation, Implementation, and Regulatory Landscape}{44}{section.7}%
\contentsline {subsection}{\numberline {7.1}Empirical Assessment of AI Trial Quality and Impact}{44}{subsection.7.1}%
\contentsline {subsection}{\numberline {7.2}Reporting Guidelines for AI Interventions (CONSORT-AI, SPIRIT-AI)}{46}{subsection.7.2}%
\contentsline {subsection}{\numberline {7.3}Regulatory Strategies and Frameworks for AI as Medical Devices}{48}{subsection.7.3}%
\contentsline {section}{\numberline {8}Conclusion and Future Directions}{50}{section.8}%
\contentsline {subsection}{\numberline {8.1}Synthesis of Key Advancements}{50}{subsection.8.1}%
\contentsline {subsection}{\numberline {8.2}Unresolved Tensions and Future Research Avenues}{52}{subsection.8.2}%
\contentsline {section}{References}{56}{section*.2}%
